Abstract: Methods of determining a subject's ototoxicity risk from administration of a pharmacotherapeutic compound having an ototoxicity risk, methods of administering a pharmacotherapeutic compound having an ototoxicity risk and oligonucleotides, peptide nucleic acids, arrays, and addressable collections for performing embodiments of the methods are provided herein.
Type:
Application
Filed:
December 3, 2013
Publication date:
May 29, 2014
Applicant:
The University of British Columbia
Inventors:
Michael R. Hayden, Bruce Carleton, Colin Ross
Abstract: Provided herein are novel carbon-monoxide releasing molecules (CO-RMs) of the Formula (I): and esters, amides, salts, solvates and hydrates thereof; wherein R1 and R2 are as described herein. Also provided are pharmaceutical compositions comprising these compounds, methods of their preparation, and their use in the treatment of liver disease and inflammation.
Type:
Application
Filed:
April 19, 2012
Publication date:
May 22, 2014
Applicant:
ALFAMA, INC.
Inventors:
Walter Anton Blättler, Carlos J.R.C. Romäo, Sandra Sofia Pereira, Lukas Adrian Kromer, Leo Edmond Otterbein, David John Gallo
Abstract: Disclosed are a class of platinum compounds with a leaving group of malonic acid derivatives containing amino and alkylamino, their pharmaceutically acceptable salts, their preparation methods and pharmaceutical composites comprising them. Disclosed also are for the uses of the compounds in the treatment of cell proliferative diseases, particularly for the treatment of cancers. The present platinum compounds have high water solubility and low toxicity.
Type:
Application
Filed:
July 6, 2012
Publication date:
May 22, 2014
Applicant:
BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD.
Abstract: The present invention is a platinum(II) compound comprising a beta-diketonate ligand represented by the following general formula: Or general formula: wherein R1 and R2 are independently selected from the group consisting of alkyl optionally substituted, heteroalkyl optionally substituted, and aryl optionally substituted; R3 and R4 are independently selected from the group consisting of ammonia, an optionally substituted heterocycle including at least one nitrogen, and an optionally substituted amine, or R3 and R4 can be joined together to form a bidentate ligand Z and Y are independently selected from the group consisting of O and S, provided at least one of Z and Y is S; and X— is a counterion. These compounds are useful in the treatment of cancer.
Abstract: This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer cells that are homologous recombination-deficient are likely to be susceptible or resistant to PARP inhibitors and platinating agents are provided.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
May 20, 2014
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., pancreatic cancer, colon cancer, brain cancer) by increasing DNA damage, reducing nucleotide synthesis, and reducing base excision repair (BER).
Type:
Application
Filed:
April 20, 2012
Publication date:
May 15, 2014
Applicant:
University of Florida Research Foundation
Inventors:
Satya Narayan, Aruna S. Jaiswal, David A. Ostov, Sukwon Hong
Abstract: Platinum compounds, modified by conjugation with thiol-containing moieties, such as cysteine or N-acetyl cystein (NAC), and pharmaceutical compositions including the modified platinum compounds. Methods for treatment of a malignancy including administering and activating the modified platinum compounds.
Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
Type:
Application
Filed:
October 24, 2013
Publication date:
May 15, 2014
Applicant:
University of Tennessee Research Foundation
Inventors:
Mitchell S. Steiner, Mary Ann Johnston, Michael L. Hancock, Jeffrey G. Hesselberg, James T. Dalton
Abstract: The invention relates to the use of a low-polyamine-content food composition for use in the treatment and/or prevention of neuropathic pain induced by a platinum salt.
Type:
Application
Filed:
November 30, 2011
Publication date:
May 8, 2014
Inventors:
David Balayssac, Mathilde Bayet-Robert, Jérémy Ferrier, Jacques Moulinoux
Abstract: The present invention provides a multi-component encapsulated reactive formulation comprising a mixture of two or more dry powder components, where each dry powder component is formed from a phase inversion process involving vigorous mixing. The dry powder is stabilized by hydrophobic colloidal particles, which assist in generating stable “dry water” microdroplets. One dry powder component comprises hydrophobic colloidal particles encapsulating microdroplets comprising an aqueous solution of one reactant, and the at least one other dry powder component comprises hydrophobic colloidal particles encapsulating microdroplets comprising an aqueous solution of another reactant. When the encapsulated formulation is agitated such that the encapsulates are broken, the encapsulates rupture and the two aqueous solutions undergo a reaction upon contact.
Type:
Application
Filed:
October 25, 2013
Publication date:
May 1, 2014
Applicant:
Pibed Limited
Inventors:
John David Hines, Bernard Paul Binks, Pierre Bruno Grascha
Abstract: A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD+, or a substance involved in the metabolism of any of these substances.
Type:
Application
Filed:
February 24, 2012
Publication date:
April 17, 2014
Applicants:
KABUSHIKI KAISHA YAKULT HONSHA, KEIO UNIVERSITY
Abstract: The present invention provides, in part, compositions and methods for treating cancer using a combination of C6-ceramide and other anti-cancer agents.
Abstract: Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
April 15, 2014
Assignee:
THe UAB Research Foundation
Inventors:
Vance G. Nielsen, James F. George, James K. Kirklin
Abstract: The present invention provides an antitumor agent comprising cisplatin and a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent life-prolongation effect in advanced gastric cancer patients that is superior to that of the standard therapy in Europe and the U.S. using an agent that contains 5-FU and does not contain a dihydropyrimidine dehydrogenase inhibitor, by way of selecting the patients based on dihydropyrimidine dehydrogenase.
Abstract: The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer.
Type:
Application
Filed:
October 7, 2013
Publication date:
April 10, 2014
Applicants:
The Ohio State University Research Foundation, Wayne State University
Abstract: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.
Type:
Grant
Filed:
August 13, 2007
Date of Patent:
March 25, 2014
Assignees:
University of Washington, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventors:
E. Peter Greenberg, Ehud Banin, Eyal Banin, Eduard Berenshtein, Mordechai Chevion
Abstract: The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.
Type:
Application
Filed:
November 8, 2013
Publication date:
March 20, 2014
Applicants:
The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
Inventors:
Stephen J. Lippard, Shanta Dhar, Omid C. Farokhzad, Frank X. Gu, Nagesh Kolishetti
Abstract: Methods of treating a head and neck cancer are disclosed.
Type:
Grant
Filed:
August 2, 2013
Date of Patent:
March 18, 2014
Assignees:
Foundation Medicine, Inc., UCL Business PLC
Inventors:
Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Roman Yelensky, Garrett Michael Frampton
Abstract: The present invention provides pharmaceutical compositions and methods for making the same, which are highly effective against cancer, viruses, amoebae, bacteria (both gram-negative and -positive), fungi, algae, bacterial spores, yeast, and the like. The compounds preferably rely on employing the synergistic effect of organo-metal compounds and the concomitant generation of reactive oxygen species (ROS) through the agency of reducing cofactors. The aqueous solution may be condensed and dried using conventional methods available to those skilled in the art to produce gels as well as solids, such as tablets or powders. Solid forms include tablets, capsules, suppositories, and the like or mixtures thereof. In addition, the solid form of the present compositions may be activated upon solubilization in a liquid.
Abstract: The described invention provides methods for treating pulmonary cancer in a subject, by administering to the subject by inhalation a composition of inhalational lipid cisplatin (ILC) comprising a lipid-complexed cisplatin.
Type:
Application
Filed:
September 4, 2013
Publication date:
March 6, 2014
Inventors:
Forrest H. Anthony, Matthew M. Parris, Edwin J. Thomas, Guangtao Zhang
Abstract: The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.
Abstract: Provided are compositions and methods to treat liver cancer and related disorders in human or veterinary individuals. Primary liver cancers, including those metastatic to other parts of the body, as well as many cancers metastatic to the liver, can be treated. The treatments comprise the administration of pharmaceutically acceptable gallium compositions, including gallium maltolate. Routes of administration include, without limitation, oral, intravenous, intratumoral, and in association with chemoembolization.
Abstract: The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization.
Type:
Grant
Filed:
April 17, 2003
Date of Patent:
March 4, 2014
Assignee:
Molteni Therapeutics S.r.l.
Inventors:
Gabrio Roncucci, Donata Dei, Giacomo Chiti, Lia Fantetti, Francesco Giuliani, Giulio Jori, Gian Maria Rossolini
Abstract: The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment and prevention of bone disorders such as osteoporosis. The composition preferably comprises strontium carbonate and strontium chlorides. Further included may be a vitamin D compound, preferably vitamin D3.
Abstract: The present invention provides pharmaceutical compositions comprising phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV). In some embodiments, such compositions may be useful for treating cancers, including cisplatin- and carboplatin-resistant cancers. The provided phosphaplatin complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum agents that have a different molecular target than those in the art.
Abstract: The present invention discloses vanadium-based insulin-mimetic agent composite coatings, application of these coatings onto implantable devices, and use of the implantable devices for accelerating osseous healing. The invention also encompasses methods of manufacturing implantable devices coated with vanadium-based insulin-mimetic agent composite coatings and the implantable devices so manufactured. The implantable devices have wide applications, including but not limited to treating bone fracture, bone trauma, arthrodesis, and other bone deficit conditions, as well as bone injuries incurred in military and sports activities.
Type:
Application
Filed:
December 9, 2011
Publication date:
February 13, 2014
Applicant:
University of Medicine and Dentistry of New Jersey
Inventors:
Sheldon S. Lin, David N. Paglia, Eric Breitbart, Joseph Benevenia
Abstract: Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.
Type:
Grant
Filed:
July 14, 2010
Date of Patent:
February 11, 2014
Assignee:
The Board of Trustees of the Southern Illinois University
Inventors:
Vickram Ramkumar, Debashree Mukherjea, Len Rybak
Abstract: Methods of treating a head and neck cancer are disclosed.
Type:
Application
Filed:
August 2, 2013
Publication date:
February 6, 2014
Applicants:
UCL BUSINESS PLC, FOUNDATION MEDICINE, INC.
Inventors:
Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Roman Yelensky, Garrett Michael Frampton
Abstract: Complex metal-containing matrices, and especially chromium-containing matrices are produced from a water soluble preparation that is derived from an item suitable for animal (and most typically human) consumption. In particularly contemplated aspects, the water soluble preparation is an extract or filtrate of disintegrated brewer's yeast, and the so prepared complex mixture is combined with a chromium-3+ ions.
Type:
Grant
Filed:
July 1, 2011
Date of Patent:
February 4, 2014
Assignee:
VDF Futureceuticals, Inc.
Inventors:
Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
Abstract: A thermosensitive liposome for the delivery of active agents and a composition thereof are disclosed, wherein the liposome comprises at least one phosphatidylcholine, at least one phosphatidylglycerol and at least one lysolipid, and the gel to liquid phase transition temperature of said liposome is from 39 0° C. to 45° C.
Abstract: The present invention regards compositions and methods for treating chronic lymphocytic leukemia in the in vivo tissue environment using selenium-containing compositions. In particular aspects, a selenium-comprising compound is administered to an individual wherein the CLL cells are in a stromal cell environment, wherein stromal factors modulate the selenium comprising compound to enhance its activity.
Type:
Application
Filed:
November 22, 2011
Publication date:
January 30, 2014
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Peng Huang, Wan Zhang, Michael J. Keating
Abstract: A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.
Type:
Grant
Filed:
May 4, 2010
Date of Patent:
January 28, 2014
Assignee:
Aridis Pharmaceuticals
Inventors:
Satoshi Ohtake, Vu Truong-Le, David Lechuga-Ballesteros, Luisa Yee, Binh V Pham, Russell Martin, Atul Saxena
Abstract: Use of tellurium-containing compounds for treating conditions in which inhibition of caspase-1/interleuFkin-1? enzyme (ICE) is beneficial is disclosed.
Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.
Type:
Application
Filed:
April 21, 2011
Publication date:
December 26, 2013
Applicant:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Inventors:
Alexei Vazquez, Darren Carpizo, Arnold Levine
Abstract: Disclosed are compositions and methods for assessing the apoptosis and survival BAD phosphorylation pathway (BAD pathway); and/or (2) the cell cycle role of APC in cell cycle regulation pathway (APC pathway); and/or (3) the transcription CREB pathway (CREB pathway) and for using these pathways to assess, treat, monitor, prognose, diagnose, etc. subjects with cancer. Also disclosed are compositions and methods for identifying molecular pathways that are common to one or more chemotherapeutic agents for the treatment of an oncological disorder, for screening for compounds or agents that can be used to treat ovarian cancer, and for selecting for compounds or agents that can enhance the cytotoxic response of cisplatin, carboplatin, and/or paclitaxel against a cancer cell, such as an ovarian cancer cell or cell line.
Type:
Application
Filed:
March 5, 2012
Publication date:
December 26, 2013
Applicant:
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Abstract: The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.
Type:
Application
Filed:
March 2, 2011
Publication date:
December 19, 2013
Applicant:
INSTITUT DE CANCEROLOGIE DE L'OUEST
Inventors:
Catherine Guette, Olivier Coqueret, Benjamin Barre, Erick Gamelin
Abstract: This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly, wherein the oxaliplatin and C6-ceramide are in amounts such that the apoptosis induced by the combination of oxaliplatin and C6-ceramide is greater than the apoptosis induced by contacting the cancer cell with either oxaliplatin alone or C6-ceramide alone. This invention also provides a method of decreasing the size of a tumor, which method comprises contacting the tumor with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly, wherein the oxaliplatin and C6-ceramide are in amounts such that the decrease in tumor size induced by the combination of oxaliplatin and C6-ceramide is greater than the decrease in tumor size induced by contacting the tumor with either oxaliplatin alone or C6-ceramide alone.
Abstract: Compositions that include vanadium or vanadyl chelated to an amino acid are disclosed, particularly vanadium or vanadyl chelated to creatine, arginine, citrulline, taurine, phenylalanine, glutamine, glutathione, leucine, or combinations thereof. In addition, compositions that included blended forms of such chelates and/or vanadyl sulfate and one or more unbound amino acids. Still further, the compositions disclosed may further include one or more additional proteins, amino acids, vitamins, minerals, or combinations thereof, which impart an additional nutritional and/or therapeutic benefit to the composition.
Abstract: The present invention describes a polyamide textile fiber comprising conjugated nanoparticles homogeneously dispersed in the fiber, selected from polyethylene glycol-conjugated platinum nanoparticles, hyaluronic acid-conjugated gold nanoparticles and mixtures thereof. The invention also describes how to obtain it as well as its use in a cosmetic skin treatment as a system for the release of said conjugated nanoparticles.
Type:
Application
Filed:
July 28, 2011
Publication date:
November 14, 2013
Applicant:
NYLSTAR, S.A.
Inventors:
Alfonso Cirera Santasusana, Esteve Soy Fabra
Abstract: The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a compound including platinum (e.g., platinum(II) or platinum(IV)) compound comprising a beta-diketonate ligand.
Abstract: Provided are fibrous composites prepared by methods of the present invention, comprising oxides and biodegradable polymers, in which the fibers are made of aerogel-like oxide materials having nanometer-sized pores. The fibrous composition advantageously has, at least, the following characteristics: (i) a very high nanoporous surface area, which also permits nucleation of crystallites; (ii) mesoporous/macroporous interspacial networks between the fibers, providing high bioactivity and a high transport rate; (iii) macropores for natural bone-like tissue growth; (iv) good mechanical properties for handling and for implant support; and (v) biodegradability for implant dissolution and time-variable mechanical properties. Further provided are methods for using the bioactive biodegradable fibrous composites as osteogenic composite materials for tissue engineering, tissue re-growth, bone implants, and bone repair, and/or for the delivery of drugs or therapeutic compounds.
Type:
Grant
Filed:
March 14, 2003
Date of Patent:
November 12, 2013
Assignee:
The Trustees of the University of Pennsylvania
Abstract: Methods for selecting chemotherapeutic agents for treating a cancer are provided that include the steps of providing a cancer cell sample having a population of bulk cancer cells and a population of cancer stem-like cells, culturing a first portion of the cancer cell sample in a hydrodynamic focusing bioreactor under microgravity conditions and for a period of time to selectively enhance the population of cancer stem-like cells and selectively kill the population of bulk cancer cells, contacting the cancer stem-like cells with one or more chemotherapeutic agents, and then selecting the one or more chemotherapeutic agents for treating the cancer if there is an increase in an amount of cytotoxicity. Methods for treating a cancer are also provided in which the identified chemotherapeutic agents are administered to a subject. Further provided are methods for identifying a test compound useful for treating a cancer.
Type:
Application
Filed:
March 19, 2013
Publication date:
November 7, 2013
Applicant:
Marshall University Research Corporation
Inventor:
Marshall University Research Corporation
Abstract: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, an ?-amino acid, an oxidant and water is provided along with temperature conditions to effectively form nanoparticles. These biocompatible nanoparticles may be further conjugated to biologically active agents, such as plasmid DNA, siRNA or proteins, such that a cell transfection agent is formed.
Type:
Application
Filed:
April 17, 2013
Publication date:
October 17, 2013
Applicant:
Cerion Enterprises, LLC
Inventors:
Wendi Ann Costanzo, Kenneth Joseph Reed, Bradford Michael Stadler
Abstract: A sunscreen composition for application for plants comprises Titanium Dioxide (TiO2), Zinc Oxide (ZnO), Silicon Dioxide (SiO2), a surfactant, wetting agent, dispersant (SWD) and water. The composition forms a suspension concentrate when combined that when diluted in water provides a solution that provides uniform coverage using convention spraying equipment. A method of protecting plants including turfgrass from ultraviolet radiation, heat stress and/or sunburn comprises combining TiO2, ZnO, SiO2, SWD and water to form a suspension concentrate. The suspension concentrate is then diluted in water and applied to an area in which sun protection is desired.
Abstract: This invention relates to complexes of certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including molybdenum, having a hydroxy acid [HA] and an amino acid [AA] moiety concurrently bound to a single said metal and having a spirocyclic, bidentate chelate structure of formula (I). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation.
Abstract: The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.